...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Insights into the structural dynamics of Liver kinase B1 (LKB1) by the binding of STe20 Related Adapter (STRAD) and Mouse protein 25 (MO25) co-activators
【24h】

Insights into the structural dynamics of Liver kinase B1 (LKB1) by the binding of STe20 Related Adapter (STRAD) and Mouse protein 25 (MO25) co-activators

机译:通过STE20相关衔接子(StraD)和小鼠蛋白25(MO25)共激活剂的结合探讨肝激酶B1(LKB1)的结构动力学

获取原文
获取原文并翻译 | 示例
           

摘要

LKB1, the tumour suppressor, is found mutated in Peutz-Jeghers syndrome (PJS). The LKB1 is a serine-threonine kinase protein that is allosterically activated by the binding of STRAD and MO25 without phosphorylating the Thr212 present at activation loop. The present study aims to highlight the structural dynamics and complexation mechanism during the allosteric activation of LKB1 by these co-activators using molecular dynamics simulations. The all atom simulations performed on the complexes of LKB1 with ATP, STRAD, and MO25 for a period of 30ns reveal that binding of STRAD and MO25 significantly stabilizes the highly flexible regions of LKB1 such as ATP binding region (1-2 loop), catalytic & activation loop segments and G helix. Also, binding of STRAD and MO25 to LKB1 promotes coordinated motion between N- and C-lobes along with the catalytic & activation loops by forming H-bonds between LKB1 and co-activators, which further facilitate to establish the conserved attributes of active LKB1 such as (i) formation of salt bridge between Lys78 and Glu98, (ii) formation of stable hydrophobic R- and C-spines, and (iii) interaction between both catalytic and activation loops. Especially, the residues of LKB1 interacting with STRAD (Arg74, Glu342) and MO25 (Glu165, Pro203 and Phe204) are observed to play a significant role in stabilizing the (LKB1-ATP)-(STRAD-ATP)-MO25 complex. Overall, the present work highlighting the structural dynamics of LKB1 by the binding of allosteric co-activators is expected to provide a basic understanding on drug design specific to PJS syndrome.
机译:LKB1,肿瘤抑制剂,被发现在Peutz-Jeghers综合征(PJS)中突变。 LKB1是丝氨酸苏氨酸激酶蛋白,其被血液和MO25的结合构成,而不在活化环中存在的THR212磷酸化。本研究旨在通过使用分子动力学模拟的这些共激活剂在LKB1的变构激活过程中突出结构动力学和络合机制。在Hyp,strad和mo25的LKB1的复合物上进行的所有原子模拟,揭示了血栓和MO25的结合显着稳定了LKB1的高度柔性区域,例如ATP结合区域(1-2环),催化剂&激活循环段和G螺旋。而且,通过在LKB1和共振活化剂之间形成H键,通过在LKB1和共激活剂之间形成H键,促进与催化和活化环之间的与催化和活化环之间的配位运动促进与催化和活化环之间的配位运动。进一步有助于建立活性LKB1的保守属性如(i)在Lys78和Glu98之间形成盐桥,(ii)形成稳定的疏水性R-和C刺,(III)催化和活化环之间的相互作用。特别是,观察到与血栓(Arg74,Glu342)和Mo25(Glu165,Pro203和PHE204)相互作用的LKB1的残基在稳定(LKB1-ATP) - (Strad-ATP)-MO25复合物方面发挥重要作用。总体而言,通过颠覆式共激活剂结合强调LKB1结构动态的本作能够对PJS综合征的药物设计提供基本的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号